CEP-701 Is a JAK2 Inhibitor Which Attenuates JAK2/STAT5 Signaling Pathway and the Proliferation of Primary Cells from Patients with Myeloproliferative Disorders.

Abstract

Small molecule tyrosine kinase inhibitors have had dramatic clinical efficacy in chronic myelogenous leukemia. The identification of a specific activating mutation (V617F) in the gene encoding Janus Kinase 2 (JAK2) in a large proportion of patients with myeloproliferative disorders (MPDs) suggests that a kinase inhibitor might have similar clinical utility. CEP-701 is an orally-active inhibitor of receptor tyrosine kinases including FLT-3, and is currently in phase II clinical trials in acute myeloid leukemia (AML) for patients with FLT-3 mutations. The ability of CEP-701 to inhibit JAK2 and suppress the growth of cells from patients with MPDs was evaluated. In in vitro kinase assay CEP-701 inhibited wild type JAK2 (IC50 l nM). In addition, CEP-701 inhibited: constitutive JAK2/STAT5 signaling in human HEL92.1.7 erythroleukemia cell line homozygous for the V617F mutation (IC50 10 nM); growth of HEL92.1.7 cells in vitro (IC50 of 30–100 nM depending upon assay and serum conditions); and growth of HEL92.1.7 xenografts in nude mice. To test whether these observations could extend to clinical samples from MPD patients, peripheral blood cells from patients with MPDs were collected and CD34+ cells were isolated using immunomagnetic separation. Cells were cultured in the presence of stem cell factor, interleukin 3 and interleukin 6 for 5 days, followed by the addition of erythropoietin for up to 5 days. Between days 7 and 10, cells were incubated in the presence of CEP-701 (up to 300 nM) and proliferation was assayed after 24 to 72 hours using the tetrazolium dye XTT. Flow cytometry and morphological examination confirmed that culture conditions strongly favored erythroid proliferation, with loss of expression of CD45 and the stepwise expression of high levels of CD71 and glycophorin A; cell expansion was more than 100-fold. Concentrations of ≤100 nM CEP-701 inhibited (> 50%) the growth of cells from 2/4 patients with polycythemia vera (PV), 10/11 with essential thrombocythemia (ET), and 2/2 with agnogenic myeloid metaplasia (AMM), as well as one AML sample from a patient with a prior history of PV. The JAK2 V617F mutation was detected by allele specific PCR and restriction analysis in mononuclear cells from 6 of 11 ET samples (6/10 inhibited), 3 of 4 PV samples (2/2 inhibited) and 1 of 2 AMM samples, as well as the AML sample. In contrast, CD34+ cells from 4 normal bone marrows cultured identically were not significantly inhibited. Biochemical analysis confirmed that in maturing erythroid cells CEP-701, at 30–100 nM, strongly inhibited JAK2/STAT5 and AKT signaling. In addition, CEP-701 suppressed expression of BclxL and cyclin D1/D2, the downstream targets of the JAK2/STAT5 pathway involved in proliferation of progenitor cells. These results demonstrate that in primary cells derived from patients with MPDs, CEP-701, in clinically achievable concentrations, inhibits constitutive JAK2/STAT5 signaling driven by the wild type and V617F JAK2 and inhibits the proliferation of cells from patients with MPDs. CEP-701 holds promise as a therapeutic agent for patients with MPDs.

Non ST-segment elevation myocardial infarction in patient with essential thrombocythemia

“…JAK2 is a member of the Janus family of cytoplasmic non-receptor tyrosine kinases. A guanine-to-thymidine substitution, which results in a substitution of valine for phenylalanine at codon 617 of JAK2 (JAK2V617F), is responsible for the constitutively activity of this tyrosine kinase that activates signal transducer and activator of transcription (STAT), mitogen activated protein kinase (MAPK) and phosphotidylinositol 3-kinase (PI3K) signalling pathways, and transforms haematopoietic progenitor cells [ 14 - 16 ]. The discovery of JAK2V617F has led to the development of selective JAK2 inhibitors for the treatment of PV, ET and PMF (6, 16).…”